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2  Endophenotypes and their Applicability 
 
Abstract 
 
Endophenotypes have shown great promise in furthering our understanding of schizophrenia 
genetics by breaking the large spectrum of schizophrenia findings into smaller phenotypes, 
assuming there are smaller genetic links to each one of these endophenotypes. 
Neurophysiological and neurocognitive measures are assessed through a number of different 
tests and, based on these findings, genetic linkage studies are then made to try to map 
relevant loci and match them to the different processes reflected by corresponding 
endophenotypes. 
We conducted a review of the available literature on several endophenotypes that are 
currently being used in genetic research to assess to which degree they are useful and further 
understand what information can be retrieved by using them. 
Methods: Pubmed was used to retrieve recent articles regarding schizophrenia 
endophenotypes, with further articles being selected after analysis of relevant references from 
our selected pool of articles. 
Results: Six neurophysiological and neurocognitive endophenotypes were reviewed to assess 
their fulfillment of endophenotype criteria, and the ease of usage in schizophrenia research. 
Available data on their association with schizophrenia genetics was also included. 
Conclusions: Several endophenotypes are currently being used to conduct genetic research in 
an attempt to map genetic abnormalities in schizophrenia. Current research is still insufficient 
and further studies are required to replicate some findings, but overall endophenotypes show 
great promise in uncovering the neurobiology of schizophrenia in a genetic level. 
 
Keywords: Prepulse inhibition; antisaccade performance; P50 suppression; working 
memory; verbal declarative memory; sustained focus attention  
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Heredity and Schizophrenia: Endophenotypes and their Applicability 
 
Schizophrenia is a psychiatric disease affecting 0,5-1% of the world population, 
typically associated with paranoid delusions, disorganized speech and thinking and auditory 
hallucinations, severely impairing any individual’s social behavior and undermining social 
relations
1
.   Even though a large number of genetic loci have been positively identified as 
schizophrenia-related, the pursue of genetic information related to psychiatric diseases met 
with difficulties: schizophrenia has a heritability described as as high as 80% - however, 
research has failed to identify a strong, single causative mutation so far
1
. There have been 
many candidate genes and chromosomal sites implied in the etiology of schizophrenia, 
mainly because of the large size of genetic sites involved, polygenic inheritance and 
epigenetic influence. 
2
 Given these challenges, a different approach to genetic research in the 
schizophrenia context emerged: instead of trying to link large syndromic findings to genetic 
alterations, some researchers attempted to break down these findings in smaller phenotypes 
and then try linking them to smaller genetic variations. The concept of endophenotype was 
created based on this theory, describing “internal phenotypes discoverable by a biochemical 
test or microscopical examination”3,4. Generally speaking, an endophenotype would allow for 
dissection of a complex phenotypical image in several smaller phenotypes, since small 
genetic alterations would be associated with small functional changes, that would, as a whole, 
match the overall phenotype in study; it would also imply that the genetical and functional 
abnormality would be more strongly associated than the association with the illness 
phenotype as a whole 
5
. The original definition of an endophenotype was further adapted as 
research progressed, with the current definition of a robust endophenotype being described as 
fulfilling the following criteria
3,6
: 
1. Showing at least moderate effect sizes between schizophrenics and controls, 
2. Deficits also present between unaffected family members and controls, 
3. Being heritable, stable and showing reliability when measured between the different sites 
of the study, 
4. Having at least some degree of evidence to a neurobiological substrate related to 
schizophrenia, 
5. Reports on these measures are significant enough to suggest they can be used to test 
genetic loci associated with schizophrenia, 
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 Medication was not associated with irreversible alterations between schizophrenics 
and controls, meaning that the alterations in the results of both groups could not be fully 
attributed to them. 
Besides these criteria, endophenotypes should also be easily and quickly measured, allowing 
for the usage of large samples to provide statistic significance to candidate endophenotypes, 
while also reducing effort for study participants.
7
 
These criteria were recently used in a large multi-centered family-based study 
organized by the Consortium on the Genetics of Schizophrenia (COGS), the first study of its 
kind to try to apply endophenotypes to retrieve information from a large sample of 
schizophrenia patients and their families. The COGS researchers selected six endophenotypes 
to be assessed from their population samples, and research is currently ongoing with some 
preliminary results already available
8
. 
 
 Methods 
 
With the aim of reviewing current information regarding schizophrenia 
endophenotypes, a search was conducted on Pubmed in December 2014 with the query 
“schizophrenia AND (endophenotype OR endophenotypes)”. The search was restricted to the 
last five years, to studies with humans and to articles published in English or Portuguese.  
From the 114 search results, articles were selected or discarded based on the relevance 
of their abstracts and/or full texts, according to our objectives. We also gave preference to 
articles relating to the COGS study and the endophenotypes it assesses, discarding literature 
related to other endophenotypes. Reference lists from the selected articles were also reviewed 
and some relevant articles were retrieved for consultation, including some published earlier 
than the filter applied to the search. 
36 articles were eventually included to produce this work. 
 
Neurophysiological Endophenotypes 
 
Schizophrenic patients show significant impairment of several neural circuits at a 
physiological level, which are translated in terms of brain function as a diminishment of 
sensory gating. This means that schizophrenics are not capable of skimming trivial stimuli 
from the environment and retain the important stimuli, which means they cannot adjust 
themselves to multiple or repetitive stimuli from their surroundings
3,8
. Several measures can 
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be tested to assess these deficits and connect them to genetic mutations to further explain the 
genetic basis of schizophrenia. Amongst these testable traits we will review P50 suppression, 
prepulse inhibition of the startle response and the antisaccade task, all of which have been 
selected as endophenotypes by the ongoing COGS study
6
. 
 
P50 Suppression 
 
The P50 wave is an auditory evoked potential, typically occurring after an acoustic 
stimulus. In normal conditions, the P50 wave is diminished if a second stimulus is presented 
shortly after. P50 suppression is thought to be related to the brain inhibitory control to focus 
on a particularly relevant stimulus by blocking other, less important stimuli
9
. Schizophrenics 
show deficits in P50 suppression, meaning that P50 waves on an electroencephalogram are 
more marked than in healthy controls, which can explain symptoms of persistent background 
noises that the patient is unable to filter out, hypervigilant states and attention and focus 
difficulties
10
. On a molecular level, this might be explained by a reduced expression of α7 
nicotinic acetylcholine receptors in neurons, which in turn reduces the ability of these cells to 
release gamma-aminobutyric acid (GABA). GABA is an inhibitory neurotransmitter 
responsible for inhibiting cerebral responses to repeated stimuli, which can explain why the 
P50 wave is insufficiently diminished in schizophrenics
10
. P50 suppression assessments 
compare the amplitude of P50 waves after both stimuli, measuring the ratio between the first 
(test) and second ( P50 wave) amplitudes, which diminishes reliability since the two variables 
are not independent. It is relatively state-independent, although some improvement in P50 
ratios in schizophrenic patients medicated with a number of antipsychotic drugs have been 
reported
9,11
. Insufficient P50 suppression has been found in schizophrenic patients and first-
degree non-affected family members and is a heritable trait, justifying its validity as an 
endophenotype
3
.  
  
Prepulse Inhibition 
 
Schizophrenia, as well as several other disorders, is associated with alterations in the 
startle response. In a healthy individual, a weak stimulus that precedes by 30 to 300 ms a 
startling stimulus leads to a diminished startle response; however, in schizophrenia, as well as 
in other diseases, this attenuation is less marked
3
. PPI is found to be diminished in both 
schizophrenic patients and in unaffected family members, which points to the possibility of 
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being a risk marker to develop schizophrenia instead of an actual schizophrenia marker
7
. 
Acoustic stimuli are preferred to visual or tactile stimuli in terms of testing because of the 
issues arising with electroshock administration in psychotic patients. Schizophrenia is shown 
to produce normal startle responses, only with PPI being diminished, which may reflect a 
hyperresponsive state of the central nervous system to a second stimulus – it has been 
speculated that the information of the first stimulus is thus in higher risk of being degraded, 
which disrupts regular cognitive responses and behavior. However, there is no evidence 
suggesting the abolishment of the prepulse processing, nor that this altered processing 
impairs cognitive functions
7
. Studies have related PPI to subcortical and cortical circuits, and 
reverse genetics have identified a large number of genes associated with a reduction in PPI
7
. 
However, being an auditive potential, the PPI is mainly influenced by the pedunculopontine 
nucleus, a structure that is not associated strongly with schizophrenia models, raising 
questions when it comes to applying it to predict clinical outcomes in schizophrenic 
patients
7,12
. PPI has been established as a potential endophenotype: significant data 
suggesting its heritability and higher prevalence in non-schizophrenic first-degree relatives 
has been collected, as well as the most reliable form of PPI: using intense prepulses and 30 to 
120 ms intervals between prepulse and startling stimulus 
7,13
. However, PPI has not been 
identified as a stable trait by all studies, with contradictory evidence concerning the degree to 
which PPI levels are influenced by anti-psychotic medication, nicotine (smoking habits), 
gender or fatigue
14
. It has thus been suggested that PPI is not useful as a clinical biomarker, 
but should be further explored as a surrogate endophenotype for correlations with other 
endophenotypes and to better evaluate schizophrenia models, being a measure of normal 
function of specific brain circuits that are altered in schizophrenia 
13,14
. 
 
Antisaccade Performance 
 
Saccadic eye-movements require integration of several neural pathways, both in terms 
of central nervous system and muscle movement
3
. A saccade constitutes a reflex that directs 
the eye towards a stimulus – however, humans are able to consciously inhibit this reflex, 
which allows for the testing of antisaccades (AS), in which subjects are instructed to focus 
their attention on a central point and, when presented with visual stimuli to the left or right, 
look in the opposite way
15
. The AS task is thus an assessment of reflex-suppression, 
information processing and transformation, and perception. Schizophrenic patients have 
consistently been shown to exhibit inappropriate saccades when compared to healthy 
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controls, but do make some correct (and corrective) AS, which excludes miscrompehension 
of the task. AS performance has been found to be heritable and stable in time and is a reliable 
test, without significant changes in results over large periods of time
7
.  Controls have better 
scores than both schizophrenic and unaffected family members
2,15,16
. It is Most medication is 
not significantly linked to AS performance, with some evidence of improvement with 
nicotine administration or treatments with risperidone and cyproheptadine 
7
. There is some 
evidence linking AS performance to a locus on chromosome 22q11, in the site of the 
cathecol-O-methyltransferase (COMT) gene, leading researchers to propose that COMT 
dysfunction may be responsible for intereference with prefrontal cortex function, possibly by 
diminishing post-synaptic dopaminergic reactions
7,17
.  
 
Neurocognitive endophenotypes 
 
Deficits in cognitive function are currently regarded as main aspects of the 
schizophrenic spectrum of symptoms, rather than a consequence of the state of a patient. 
Different findings show that frontotemporal function is diminished in schizophrenia, pointing 
to a genetic and environmental etiology 
9
, with cognitive abnormalities showing before the 
onset of the disease
18,19
. Several cognitive deficits have been shown to be unrelated to 
antipsychotics, stable over time, and persistent throughout the disease; also, cognitive 
impairment is present, even if in a less severe way, in unaffected family members of 
schizophrenic patients, suggesting that some of these deficits may actually fulfill all criteria 
to be seen as endophenotypes 
19
. The COGS study has selected deficits in attention, verbal 
and working memory as neurocognitive endophenotypes, which will be further reviewed
6
.  
 
Attention 
 
Deficient attention is part of the range of schizophrenic symptoms, with different 
aspects of attention involved. Sustained focused attention is one of these aspects, having been 
extensively studied due its possible use as a schizophrenia endophenotype
20
. Continuous 
Performance Tests (CPT) are often used to measure sustained focused attention. CPTs consist 
in quick tasks: the subject is instructed to react to a number or letter, and a random sequence 
of numbers or letters are then presented
9,20
. Thus, CPTs can assess the ability of the subject to 
sustain focus and respond to the selected stimuli in a period of time. Simpler CPTs are able to 
detect patients at risk to develop schizophrenia, although more complex CPTs that also assess 
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working memory or perception have a higher sensibility for smaller deficits, making them 
ideal candidates for usage as an endophenotype
8,9
. Examples of such CPTs include CPT-
Degraded Stimulus (in which the target stimulus is a blurred number in a set of other blurred 
numbers, increasing perceptive demand on the subject) and CPT-Identical Pairs (the target is 
the second number on a sequence of identical numbers, which requires the subject to 
maintain every number of the sequence on their working memory)
21
.  Assessment of genes 
associated with deficits in CPT performance is still premature, with some evidence of 
possible links to some genetic alterations, mainly deletion of chromosome 22q11 and 
mutations in chromosome 6p24
9,22
. CPT performance has been found to be heritable, 
although some reservations have been brought up by researchers due to the small sample 
sizes of these studies
9,18
. Unaffected family members of schizophrenic patients have also 
shown to perform poorly when compared to controls
9,18
.  It is reliable and independent, even 
medication is not a causal factor of diminished CPT performance, instead being responsible 
for a non-significant improvement
9,23
. As such, CPT-DS and CPT-IP fulfill all the criteria to 
be used as endophenotypes, and have been included in the on-going COGS study.  
 
Verbal Declarative Memory 
 
Deficits in Verbal Declarative Memory (VDM) refer to the maintenance and 
manipulation of information through memories which can be verbally transmitted by the 
subject. It is thought that VDM has two main branches: storage of information on the one 
side, and manipulation of stored information on the other
24
. Abnormalities can affect 
acquisition, storage and retrieval of memories, being translated in, for example, learning 
deficits or increased forgetfulness
9
. Several tests exist to assess VDM: amongst these, the 
COGS study selected The California Verbal Learning Test, Second Edition (CVLT-II) a 
verbal memory and executive function test that consist in the recall of a list of 16 words in 
different points (immediately after administering the test, after a different list is administered 
and 20 minutes after administration), with the assessment of the total correct answers in all 
three measurements
6,9,25
. Schizophrenic patients show significant worse results in this test in 
relation to controls, a finding that is replicated in unaffected family members. CVLT-II 
performance is a stable and reliable test, and also state-independent, with medication not 
being causative of the worse results of schizophrenic patients
9,26
. VDM is modulated by both 
the medial temporal and frontal lobe, which in turn are dysfunctional in schizophrenics, 
meaning that an assessment of VDM might lead to clarification on genetic locations related to 
Braga D., Correia R.  9 
 
 
 
these neural circuits. Some evidence of genetic loci possibly related to VDM exists, with 
DISC1 and transalin-associated factor X genes in chromosome 1 and a locus in the long arm 
of chromosome 4 (4q21) having been recently pointed out as possibly involved in VDM and 
its associated neural pathways 
27,28
. 
 
Working Memory 
 
Working Memory (WM) is related to the processes of maintenance and manipulation 
of internal representations of stimuli. Assessment of WM deficits can be easily done by the 
Letter-Number Span (LNS) test, which requires the testee to repeat or order a set of numbers 
and letters presented in a random sequence
6,9
. Studies have found that WM deficits are not 
related to medication, manifesting themselves from the onset of the disease and during 
treatment with antipsychotics, which actually might improve the results of patients taking the 
LNS test
29,30
. WM impairment has been described as a heritable, reliable and stable deficit in 
schizophrenic patients, who have been shown to achieve low performances on low and high 
difficulty tasks when compared to controls 
2,8,31,32
. Several studies have related WM to the 
dorsolateral prefrontal cortex, which is one of the main regions affected by schizophrenia; 
some studies have linked WM deficits to the COMT gene in chromosome 22, although these 
findings have not yet been successfully replicated, leading to speculation of whether WM is 
related to COMT and the dopaminergic sytem
30,32-35
.  
 
Conclusion 
 
Endophenotypes may provide valuable tools to more easily identify the genetic basis 
of schizophrenia susceptibility. The COGS study is a substantial step forward in this aspect, 
being the first large-scale attempt to assess schizophrenia genes with a large population 
sample, although with some bias due to the specific sample population – the COGS methods 
for familial recruitment exclude families where all children or both parents are affected, as 
well as those where there is only one unaffected family member to assess
6
. Genome-wide 
studies from COGS have reported links between tested endophenotypes and a number of 
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genes, already allowing for some theorizing on the genetic common ground of some of the 
schizophrenia impairments.  
Although endophenotypes require an enormous amount of technology to fulfill their goal of 
identifying genes, the fact is that some of them might be unable to do so. Even so, these 
endophenotypes might be of use in order to understand which aspects of neural behavior are 
associated with a locus or gene, even if it is not possible to clearly identify the said locus or 
gene using only the endophenotype.  
In the future, endophenotype research might provide each group of schizophrenias with a 
characteristical endophenotypical pattern, leading to a better understanding of the different 
neurobiology of each subtype of schizophrenia. This, in turn, may allow for differential 
tailoring of therapeutic strategies, aimed at the specific gene products related to each 
endophenotype, and even allow for the development of approaches not considered so far in 
order to target different deficits. 
It should be noted that none of the endophenotypes described in this review are “perfect” 
endophenotypes according to the ideal endophenotype definition. It has been suggested that a 
composite endophenotype, an association of several endophenotypes that can be assessed at 
once, is more stable than several different endophenotypes. As such, if future studies are able 
to assess the degree of overlap between individual endophenotypes and eventually create 
multiple endophenotypes matching common genetic mutations, we could see an even more 
powerful diagnostic and research tool arising. Some results already point in this direction: the 
neurocognitive endophenotypes have a strong correlation between themselves, while also 
with the AS task, while finding that the remaining neurophysiologic endophenotypes had no 
significant correlation between them – probably because they reflect independent neural 
pathways
36
. 
In any case, endophenotype research must continue to allow a better understanding of 
schizophrenia and its genetics, and hopefully it will be successful in allowing for better 
therapies and diagnostic tools for this severely incapacitating disease. 
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